1 2 3 Rucaparib blocks SARS-CoV-2 virus binding to cells and interleukin-6 release in a 4 model of COVID-19 5 6 7 8 Henrietta Papp<sup>1,2,\*</sup>, Judit Bóvári-Biri<sup>3,\*</sup>, Krisztina Bánfai<sup>3,\*</sup>, Péter Juhász<sup>4</sup>, Mohamed Mahdi<sup>5</sup>, 9 Lilian Cristina Russo<sup>6</sup>, Dávid Bajusz<sup>7</sup>, Adrienn Sipos<sup>8,9</sup>, László Petri<sup>7</sup>, Ágnes Kemény<sup>2,10,11</sup>, 10 Mónika Madai<sup>1,2</sup>, Anett Kuczmog<sup>1,2</sup>, Gvula Batta<sup>12</sup>, Orsolva Mózner<sup>13</sup>, Dorottva Vaskó<sup>14</sup>, Edit 11 Hirsch<sup>14</sup>, Péter Bohus<sup>15</sup>, Gábor Méhes<sup>4</sup>, József Tőzsér<sup>5</sup>, Nicola J. Curtin<sup>16</sup>, Zsuzsanna 12 Helves<sup>2,10</sup>, Attila Tóth<sup>17</sup>, Nicolas C. Hoch<sup>6</sup>, Ferenc Jakab<sup>1,2</sup>, György M. Keserű<sup>7</sup>, Judit E. 13 14 Pongrácz<sup>2</sup>, Péter Bai<sup>8,9,18,19,#</sup> 15 16 <sup>1</sup>National Laboratory of Virology, University of Pécs, 7624, Pécs, Hungary and Institute of 17 18 Biology, Faculty of Sciences, University of Pécs, 7624, Pécs, Hungary 19 <sup>2</sup>Szentagothai Research Centre, University of Pécs, 7624, Pécs, Hungary 20 <sup>3</sup>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Pécs, 21 7624, Pécs, Hungary 22 <sup>4</sup>Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, 23 Hungary; 24 <sup>5</sup>Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of 25 Debrecen, 4032, Hungary; 26 <sup>6</sup>Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, 27 Brazil: 28 <sup>7</sup>Medicinal Chemistry Research Group, Research Centre for Natural Sciences, 1117, 29 Budapest, Hungary 30 <sup>8</sup>Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032, 31 Debrecen, Hungary; <sup>9</sup>MTA-DE Cell Biology and Signaling Research Group ELKH, Debrecen, 4032, Hungary; 32 <sup>10</sup>Department of Pharmacology and Pharmacotherapy, Medical School; Centre for 33 34 Neuroscience, 7624, Pécs, Hungary <sup>11</sup>Department of Medical Biology, Medical School, Pécs, 7624, Hungary 35 <sup>12</sup>Department of Organic Chemistry, Faculty of Science and Technology, University of 36 37 Debrecen, 4032, Debrecen, Hungary

<sup>13</sup>Doctoral School of Molecular Medicine, Semmelweis University, 1094, Budapest,
 Hungary and Institute of Enzymology, Research Centre for Natural Sciences, 1117,
 Budapest, Hungary

41 <sup>14</sup>Department of Organic Chemistry and Technology, Faculty of Chemical Technology and

42 Biotechnology, Budapest University of Technology and Economics, 1111, Budapest,

- 43 Hungary
- 44 <sup>15</sup>Erzsébet Hospital, Sátoraljaújhely, 3980, Hungary
- 45 <sup>16</sup>Translational and Clinical Research Institute, Newcastle University Centre for Cancer,
- 46 Faculty of Medical Sciences, Newcastle University, NE2 4HH, Newcastle upon Tyne, UK
- <sup>17</sup>Section of Clinical Physiology, Department of Cardiology, University of Debrecen,
   Debrecen, 4032, Hungary;
- <sup>18</sup>MTA-DE Lendület Laboratory of Cellular Metabolism, 4032, Debrecen, Hungary;

<sup>19</sup>Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen,

51 4032, Debrecen, Hungary;

- 52 \* equal contribution
- 53
- 54

<sup>#</sup>Correspondence can be also sent to: Peter Bai, PhD, DSc University of Debrecen, Faculty
of Medicine, Department of Medical Chemistry, 4032 Debrecen, Egyetem tér 1., Hungary,
Tel. +36 52 412 345; Fax. +36 52 412 566, e-mail: <u>baip@med.unideb.hu</u>

# 58 Abstract

59 Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 virus, is a major global 60 health challenge, as there is no efficient treatment for the moderate to severe disease. ADP-61 ribosylation events are involved in regulating the life cycle of coronaviruses and the 62 inflammatory reactions of the host, hence we assessed the repurposing of registered PARP 63 inhibitors for the treatment of COVID-19. We detected high levels of oxidative stress and 64 strong PARylation in all cell types in the lungs of COVID-19 patients. Interestingly, rucaparib, 65 unlike other PARP inhibitors, reduced SARS-CoV-2 infection rate through binding to the 66 conserved 493-498 amino acid region located in the spike-ACE2 interface in the spike 67 protein and prevented viruses from binding to ACE2. In addition, the spike protein-induced 68 overexpression of IL-6, a key cytokine in COVID-19, was inhibited by rucaparib at 69 pharmacologically relevant concentrations. These findings build a case for repurposing 70 rucaparib for treating COVID-19 disease.

- 71
- 72

### 73 Keywords:

ACE2, ARTD, atypical lung inflammation, cytokine release syndrome, COVID-19, IL6,
 intermolecular interaction, macrodomain, macrophage overactivation syndrome, NAD+,
 olaparib, PARP, PARP inhibitor, rucaparib, SARS-COV-2, SARS-COV-2 spike protein,
 stenoparib, talazoparib, viral lung inflammation

79 Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 virus infection, is a 80 global health challenge. SARS-CoV-2 is an enveloped virus with an ssRNA+ genome 81 belonging to the Coronaviridae family<sup>1</sup>. SARS-CoV-2 predominantly infects the upper airways 82 that may then transfer to lower airways causing atypical lung inflammation <sup>1</sup>. The virus uses 83 the angiotensin-converting enzyme 2 (ACE2) as cellular receptor for entry into epithelial 84 cells<sup>1</sup>. Although, 80% of the patients develop mild or no symptoms, 15% develop severe 85 disease requiring oxygen support, and 5% develop critical illness. The inflammatory 86 response during the disease strongly contributes to organ damage and critical illness. Severe 87 COVID-19 remains an unmet medical need calling for novel therapeutic modalities.

PARPs are ADP-ribosyl transferase enzymes composed of 17 members in humans
(PARP1-PARP16)<sup>2</sup>. PARP1, PARP2 and PARP3 can be activated by damaged DNA<sup>2</sup> that is
often the result of reactive oxygen species (ROS) production under inflammatory conditions<sup>2</sup>.
PARP activation contributes to necrotic and apoptotic cell death, furthermore, PARP
activation has pro-inflammatory properties<sup>2</sup>. Four small molecule pharmacological PARP
inhibitors, olaparib, rucaparib, niraparib and talazoparib are FDA/EMA-approved for cancer
therapy and fluzoparib and pamiparib are approved by the Chinese NMPA<sup>2</sup>.

95 Poly(ADP-ribosyl)ation (PARylation) of SARS-CoV-2 proteins can limit virus infectivity; a 96 protective measure of the host that can be countered by the virus macrodomain<sup>3,4</sup>. A recent 97 report suggested that stenoparib, a PARP inhibitor of both classical PARPs and tankyrases, 98 can block the replication of SARS-CoV-2<sup>5</sup>. COVID-19 is characterized by ROS production 99 and PARP activation<sup>6</sup> that can contribute to cell death and tissue damage<sup>2</sup>. Taken together, 100 PARP inhibition may have a dual pharmacological effect in COVID-19 disease, by blocking 101 both SARS-CoV-2 replication and suppressing the consequent immune reaction. We set out 102 to investigate the opportunity for repurposing registered pharmacological PARP inhibitors for 103 COVID-19.

We have observed oxidative stress, marked by 4-hydroxynonenal (4HNE) staining, and PARP activation, marked by PAR immunostaining, in the pneumocytes, endothelial cells and macrophages of the lung tissue of COVID-19 patients (**Fig1A**), highlighting a role for PARylation in COVID-19.

Next, we assessed three approved PARP inhibitors, rucaparib, talazoparib and olaparib in a cellular SARS-CoV-2 infection model in concentrations ranging up to 40  $\mu$ M. Rucaparib inhibited the infection and proliferation of the B.1.5 variant of SARS-CoV-2 virus (original Wuhan variant with D614G mutation, IC<sub>50</sub> = 27.5  $\mu$ M, **Fig1B**), while talazoparib and olaparib had no effect (**FigS1A**). Importantly, rucaparib was not toxic at concentrations that profoundly inhibited viral proliferation (the IC<sub>50</sub> value for toxicity was 64.8  $\mu$ M **Fig1B**), hence, it is not direct toxicity that limits SARS-CoV-2 infection and proliferation.

115 The IC<sub>50</sub> concentration for viral infection of rucaparib (27.5 µM corresponding to ~8.7 116 mg/L) is much higher than that achieved at the recommended dose (600 mg BID, steady 117 state level  $\sim 2.4 \text{ mg/l}^7$ ), furthermore, PARP inhibition of >90% is achieved using doses of 92. mg<sup>8</sup>. Therefore the impact on viral replication is unlikely to be due to PARP1 inhibition and 118 119 may result from binding to other targets e.g. the spike protein. We tested this hypothesis in 120 neutralization experiments. Rucaparib was preincubated with a pseudovirus bearing the 121 spike protein of SARS-CoV-2 (wild-type, delta and the omicron variants) or the SARS-CoV-2 122 virus (alpha variant) and it inhibited virus uptake of all major variants of SARS-CoV-2 (Fig. 123 **1C-D**), suggesting that rucaparib abrogates the binding of the virus to host cell receptors. 124 Rucaparib bound directly to the spike protein of SARS-CoV-2 ( $IC_{50} = 115\pm21.9 \mu M$ ) in an *in* 125 vitro assay, while no significant binding was detected for the other PARP inhibitors 126 stenoparib and olaparib at concentrations up to 500 µM (Fig. 2A). We observed 127 magnetisation transfer from the receptor-binding domain (RBD) of spike to rucaparib in 128 saturation difference spectrum NMR (STD-NMR) experiments that verifies rucaparib binding 129 to the RBD *in vitro* (**Fig2B**).

130 Next, we identified the putative binding site of rucaparib. A single binding hotspot was 131 identified at the protein-protein interaction surface of all three variants (FigS1B), 132 characterized by the residues 493-498, with further sidechains R403, E406, Y449, Y453, 133 N501 and Y505 in the vicinity (Fig2C). The predicted binding mode of rucaparib is stabilized 134 mainly by a strong ionic interaction between the negatively charged E406 sidechain and the 135 terminal methylamine group of rucaparib. The latter is a positively charged and highly flexible 136 moiety that is exclusive to this compound among the four PARP inhibitors tested in this 137 study, which is in line with the exclusive on-target affinity of rucaparib. Additional interactions 138 involve an H-bond between N501 and the NH group of the lactam unit, and back-to-back 139 cation-pi interactions between Y453 and the methylamine group, as well as R403 and the 140 phenyl ring. The STD-NMR shows magnetisation transfer (Fig2B) from RBD to H15, H16, 141 H18 and H19 of the aromatic moiety of rucaparib that verifies binding and the validity of the 142 in silico docking (Fig2C, FigS1B). Most amino acids responsible for rucaparib binding were 143 conserved among SARS-CoV-2 variants. The omicron variant harbored the highest number 144 of mutations at the binding site (Fig2D).

We assessed whether rucaparib targets the macrodomain of SARS-CoV-2 by applying a previously described model<sup>3</sup>. In agreement with previous results, Interferon- $\gamma$  (IFN $\gamma$ ) treatment induced substantial cellular ADP-ribosylation that was reduced by ~50% when the macrodomain of SARS-CoV-2 was overexpressed<sup>3</sup>. Rucaparib treatment at either 500 nM or 20  $\mu$ M did not prevent this macrodomain-dependent reduction in IFN-induced ADPribosylation relative to control cells (**FigS1C**), suggesting that rucaparib does not inhibit the

151 viral macrodomain at the concentrations tested. However, we observed a concentration-152 dependent effect of rucaparib on the overall induction of ADP-ribosylation by IFN-y (FigS1C). 153 Next, we assessed the capacity of rucaparib to inhibit the expression of interleukin-6 (IL-154 6); a central cytokine in COVID-19<sup>1</sup>. In human macrophages, challenged by bacterial 155 lipopolysaccharide (LPS), 20 µM rucaparib significantly reduced the expression of IL6, IL8 156 and IL10 at a similar or better efficacy as dexamethasone (Fig2E, FigS2A). Talazoparib (10 157 µM) and olaparib (20 µM) had no effect in this regard (data not shown). Subsequently, we 158 induced IL-6 expression in macrophages with SARS-CoV-2 spike protein, and in this system 159 rucaparib also blocked IL-6 overexpression (Fig2F) without affecting IL-1 $\beta$  and TNF $\alpha$ 160 expression (data not shown). Finally, we assessed members of the Signal Transducer and 161 Activator of Transcription (Stat) family of transcription factors (Stat1, 3, 5A, 5B), which are 162 key mediators of interferon signaling and were implicated in COVID-19<sup>9</sup>. Stat1 and Stat3 163 were activated upon poly(I:C) or spike induction that was not inhibitedrucaparib at pharmacologically relevant concentrations (FigS2B, C). Interestingly, Stat5A and 5B 164 165 activation was inhibited by spike, however, no statistically significant changes to Stat5A and 166 5B were elicited by rucaparib treatment (FigS2C).

167 We showed that rucaparib can bind to the spike protein of SARS-CoV-2 and, therefore 168 inhibit the binding of SARS-CoV-2 to the ACE2 receptor and virus entry into host cells. These 169 findings are similar to the reports on stenoparib that can inhibit SARS-CoV-2 proliferation in 170 low concentrations<sup>5</sup>. Interestingly, olaparib and talazoparib had no effect on SARS-CoV-2 171 infection and proliferation. Most amino acids responsible for rucaparib binding are conserved 172 among variants pointing out that rucaparib can be repurposed to block SARS-CoV-2 binding. 173 Furthermore, the rucaparib binding site is a potential site for drug development to target the 174 SARS-CoV-2 – ACE2 interaction.

Another important, and clinically relevant finding of the study is that rucaparib can efficiently block the expression of IL-6, the key interleukin involved in COVID-19-related inflammatory response<sup>1</sup>. In human monocyte-derived macrophages, rucaparib blunted both LPS or SARS-CoV-2 spike protein induced IL-6 overexpression. The lower rucaparib concentrations are pharmacologically relevant and are comparable to the achievable serum levels of rucaparib in humans<sup>7,10</sup>.

In the frame of this study, we assessed the applicability of pharmacological PARP inhibition in COVID-19 disease. We detected oxidative stress and PARylation in the lungs of COVID-19 patients similar to previous reports<sup>6</sup>. A large set of studies have provided evidence that PARP(1) activation is proinflammatory<sup>2</sup>. Several aspects of PARP-mediated inflammatory response have direct relevance to COVID-19-related inflammatory lung injury. Genetic or pharmacological PARP inhibition was protective in asthma, acute lung injury (burn, smoke inhalation, bacterial infection, etc.), ARDS, chronic obstructive pulmonary

disease (COPD), lung fibrosis or ventilation-induced lung injury (reviewed in <sup>11</sup>). Importantly, an overwhelming set of data point out that these findings can be translated to the human situation, for example, treatment with INO-1001; a PARP inhibitor, reduced serum IL-6 expression in humans<sup>12</sup>. The immunosuppressive effects of PARP inhibition in humans is further supported by a report<sup>13</sup> showing that patients receiving PARP inhibitors as oncological treatment produced fewer neutralizing antibodies following SARS-CoV-2 vaccination as healthy volunteers.

195 Of note, there are other PARP-related events, relevant to COVID-19, which were not tested in our study. PARP overactivation can contribute to cell death and tissue damage<sup>2,11</sup>. 196 Furthermore, PARP activation can strongly reduce cellular NAD+ levels<sup>2</sup> that was implicated 197 198 in the pathogenesis of COVID-19<sup>6</sup>. Several members of the PARP family, such as PARP9, 199 PARP11 and PARP14 were also implicated in antiviral protection, including SARS-CoV-2<sup>3,14</sup> <sup>18</sup>, often acting in different steps within the IFN signaling cascade. High doses of rucaparib 200 201 may interfere with these PARP enzymes, as high dose rucaparib impaired IFN-induced ADP-202 ribosylation.

203 Taken together, rucaparib has a dual action in COVID-19, it can disrupt the binding of 204 SARS-CoV-2 to ACE2 and it can target the inflammatory response. Although, the  $IC_{50}$  value 205 of rucaparib in disrupting the SARS-CoV-2 binding is higher than the steady state levels on 206 the dose approved for cancer therapy, rucaparib could potentially be applied as an aerosol in 207 patients to achieve higher local concentrations so rucaparib can exert its dual effects in the 208 lungs. Rucaparib, unlike the other clinically approved PARP inhibitors, was reported to continue to inhibit PARP1 for extended periods even after its removal<sup>19,20</sup>, further 209 210 strengthening the case of its repurposing. Of note, the anti-inflammatory potential of 211 rucaparib was comparable to dexamethasone, the standard of care in COVID-19, in the 212 models used in this study. PARP inhibitors can potentially be synergistic with tocilizumab, 213 and anti-IL-6 monoclonal antibody used against the cytokine storm, as well as with the anti-214 inflammatory drugs used in the therapy of COVID-19. These observations point towards the 215 repurposing of rucaparib to combat COVID-19.

216

# 217 Acknowledgement

218 The work was supported by grants from the NKFIH (K132623, K123975, K135150, K141142, 219 TKP2021-EGA-10, TKP-2021-EGA-13, TKP2021-EGA-19, TKP2021-EGA-20, TKP2021-220 NVA-07). The Projects no. TKP2021-EGA-10, TKP-2021-EGA-13, TKP2021-EGA-19, 221 TKP2021-EGA-20 were implemented with the support provided from the National Research. 222 Development and Innovation Fund of Hungary, financed under the TKP2021-EGA funding 223 scheme. Project no. TKP2021-NVA-07 has been implemented with the support provided 224 from the National Research, Development and Innovation Fund of Hungary, financed under 225 the TKP2021-NVA funding scheme. The POST-COVID2021-33 grant to PB was from the 226 Hungarian Academy of Sciences. FAPESP grants 2018/18007-5 and 2020/05317-6 were to 227 NH. The research was performed in collaboration with Cell and Tissue Culture Core 228 Facility at the Szentagothai Research Centre of the University of Pecs. The work of D.B. was 229 supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences and the UNKP- 21-5 New National Excellence Program of the Ministry for Innovation and 230 231 Technology. Prepared with the professional support of the Doctoral Student Scholarship 232 Program of the Co-operative Doctoral Program of the Ministry of Innovation and Technology 233 financed from the National Research, Development and Innovation Fund (to OM). The 234 authors are grateful to Dr. Balazs Sarkadi (Institute of Enzymology, Research Centre for 235 Natural Sciences, Budapest, Hungary) for his support and the critical revision of the 236 manuscript.

237

#### 238 Conflict of interest

Rucaparib was a generous gift from Clovis Oncology (Boulder, CO, USA). Clovis had noimpact on study design and the conclusions drawn.

241 Dr. Curtin is an inventor on patents WO 2005/012305 A2 and WO/2006/033006 with royalties

242 paid to CRUK and Newcastle University, she gives her royalty share to charity and took no

243 royalty in relation to this study.

- 244 Other authors declare no conflict of interest.
- 245

#### 246 Data availability

247 Primary data is available at <u>https://figshare.com/s/6b25fd3d5de80ab3f51e</u> (DOI:
248 10.6084/m9.figshare.19418957).

# 249 Figure captions

#### 250 Figure 1. Rucaparib inhibits the binding of SARS-CoV-2 to the host cell

(A) In lungs of controls and patients died of COVID-19 SARS-CoV-2 spike protein, 4-hydroxynonenal and poly(ADP-ribose) immunohistochemistry was performed and evaluated.
(B) The antiproliferative and toxic effects of rucaparib were tested on Vero E6 cells infected with of B.1.5 variant SARS-CoV-2. (C) Fluorescently-labelled pseudovirions were pre-treated with 35 µM rucaparib and pseudovirus uptake was assessed in HEK293T cells. (D) The alpha variant of SARS-CoV-2 was pretreated with rucaparib and was used to infect Vero E6 cells.

258

# Figure 2. Rucaparib binds to the spike protein of SARS-CoV-2, and effectively inhibits IL-6 expression

261 (A) The indicated PARP inhibitors were tested to block the spike-ACE2 interaction in an in 262 vitro binding assay. (B) STD-NMR spectrum of rucaparib alone and in complex with the 263 receptor-binding domain of spike. (C) Predicted binding mode of rucaparib (green) at the 264 protein-protein binding surface of the SARS-CoV2 RBD (fawn), with the main protein-ligand 265 interactions highlighted as dashed lines (magenta: ionic interaction, yellow: H-bond, green: 266 cation-pi interaction). (D) The sequence of the rucaparib binding site from the available 267 variants were compared. (E-F) Human primary monocytes differentiated to macrophages 268 were treated as indicated and IL-6 production was measured.

#### 269 References

- Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. & Di Napoli, R. in *StatPearls* (StatPearls Publishing, Treasure Island (FL), 2022).
- 272 2. Curtin, N.J. & Szabo, C. Nature Reviews Drug Discovery 19, 711-736 (2020).
- 273 3. Russo, L.C., et al. Journal of Biological Chemistry 297, 101041 (2021).
- 4. Fehr, A.R., et al. Genes and Development **34**, 341-359 (2020).
- 275 5. Zarn, K.E., et al. BioRxiv, <u>https://doi.org/10.1101/2021.1111.1103.467186</u> (2021).
- 276 6. Heer, C.D., et al. Journal of Biological Chemistry **295**, 17986-17996 (2020).
- 277 7. Shapiro, G.I., et al. Clin Pharmacol Drug Dev 8, 107-118 (2019).
- 278 8. Drew, Y., et al. Br J Cancer **114**, 723-730 (2016).
- 279 9. Luo, W., et al. Trends in Pharmacological Sciences 41, 531-543 (2020).
- 280 10. Wilson, R.H., et al. British Journal of Cancer **116**, 884-892 (2017).
- 281 11. Curtin, N., et al. British Journal of Pharmacology **177**, 3635-3645 (2020).
- 282 12. Morrow, D.A., et al. Journal of Thrombosis and Thrombolysis 27, 359-364 (2009).
- 283 13. Liontos, M., et al. Vaccines **9**(2021).
- 284 14. Caprara, G., et al. Journal of immunology (Baltimore, Md. : 1950) **200**, 2439-2454 (2018).
- 286 15. Daugherty, M.D., Young, J.M., Kerns, J.A. & Malik, H.S. *PLoS Genetetics* **10**, e1004403. (2014).
- 288 16. Xing, J., et al. Nature Communications **12**, 2681 (2021).
- 289 17. Guo, T., et al. Nature microbiology 4, 1872-1884 (2019).
- Tauber, A.L., Schweiker, S.S. & Levonis, S.M. *Future Medicinal Chemistry* 13, 587 592 (2021).
- 292 19. Smith, H.L., Willmore, E., Mukhopadhyay, A., Drew, Y. & Curtin, N.J. *bioRxiv*,
   293 2022.2001.2024.477471 (2022).
- 294 20. Murray, J., et al. Br J Cancer 110, 1977-1984 (2014).



Figure 1.



Delta 411-508 Epsilon 402-510 Wuhan 403-510 Alpha 400-509 Beta 400-509 Gamma 403-510 OmicronBA.1 400-507 OmicronBA.2 400-507

Delta 411-508 Epsilon 402-510 Wuhan 403-510 Alpha 400-509 Beta 400-509 Gamma 403-510 OmicronBA.1 400-507 OmicronBA.2 400-507



PFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV PFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV PFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV PFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPT<mark>Y</mark>GVGYQPYRV PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT<mark>Y</mark>GVGYQPYRV PFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPT<mark>Y</mark>GVGYQPYRV PFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRV OISTEIYQAGNKPCNGVAGFNCYFPL<mark>R</mark>SYGF**R**PT<mark>Y</mark>GVG<del>H</del>QPYRV







# Figure 2.





Rucaparib (µM) - - - 0.5 1 5 15 27

Rucaparib (µM) - - - 0.5 1 5 15 27

Figure S2.

÷

0.5 20

•

0.5 20